LIVN vs PTGX
LivaNova vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
VS
PTGX
Protagonist Therapeutics, Inc.
67
Buy
| Metric | LIVN | PTGX |
|---|
| AI Score |
70
|
67
|
| Price |
$81.48
|
$158.59
|
| P/E Ratio |
23.83×
|
127.33×
|
| ROE |
-20.2%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.2%
|
99.9%
|
| Debt / Equity |
0.27×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
60.6
|
75.9
|
| Beta |
0.872
|
1.794
|
| Expected Upside |
+0.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for LIVN versus PTGX.
LIVN leads by 3 points.
LIVN scores 70/100 (Buy) versus PTGX at 67/100 (Buy).
LIVN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- ROE of 15.4% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Risk/reward is unfavorable: 5.6% downside vs 0.8% upside.
PTGX Committee View
83% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 119.8 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 119.8 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- RSI at 76 is in overbought territory — Technical